Loading
Latest filing published 31 Mar 2026 for Hesai Group - W.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Li Yifan, listed as chief executive, has filed trades across 2 companies (mainly through HKEX), most often in Everest Medicines Ltd. and Hesai Group - W. The record holds 3 filings, for trades running from 14 July 2021 to 25 March 2026.
No open-market sale appears; the market trades are 3 purchases. The amount is not disclosed for 3 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2026, the count stands at 1 purchase and no sales.
On 31 March 2026 came the latest disclosure, an open-market purchase in Hesai Group - W. Typically, a trade is published a median of 6 days after it takes place. This delay matters because a trade only becomes useful information once it is public. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration